Public deliberation to assess patient views on biosimilar medication switching for the treatment of inflammatory bowel disease

• Asıl Yazarlar: Kerry A. Ryan (Yazar), Shirley Cohen-Mekelburg (Yazar), Jessica A. Baker (Yazar), Eileen M. Weinheimer-Haus (Yazar), Chris Krenz (Yazar), Jason K. Hou (Yazar), Raymond De Vries (Yazar), Akbar K. Waljee (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: BMC, 2024-10-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Abstract Background Biosimilars are highly similar, but not identical, versions of originator biologic medications. Switching patients to biosimilars presents an opportunity to mitigate rising drug costs and expand patient access to important biologic therapies. However, decreased patient acceptance...